AC-P19M peptide

AC-P19M peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-FAKKLAKLKKKLAKLALAL-OH

H-Phe-Ala-Lys-Lys-Leu-Ala-Lys-Leu-Lys-Lys-Lys-Leu-Ala-Lys-Leu-Ala-Leu-Ala-Leu-OH

19

95.39%

C₁₀₂H₁₈₆N₂₆O₂₀

2096.72

Synthetic

Powder

AC-P19M is a novel anticancer peptide designed de novo using in silico methods, as described in the research paper by Shin et al. The peptide was developed through functional prediction and sequence modification based on existing peptide sequences in databases. It exhibits potent anticancer activity against lung cancer cells (A549 and H460) by disrupting cellular membranes, inducing apoptosis, and inhibiting migration and invasion of cancer cells. AC-P19M also demonstrates anti-angiogenic effects by inhibiting VEGF receptor 2 signaling, which is crucial for angiogenesis in endothelial cells. The peptide shows high selectivity for cancer cells with low toxicity towards normal cells, making it a promising candidate for targeted cancer therapy. Physiochemically, AC-P19M has a net charge increase, decreased hydrophobicity, and increased hydrophobic moment compared to its precursor peptide AC-P19. Experimental results confirm that AC-P19M has stronger anticancer activity than AC-P19, with enhanced cytotoxic effects on cancer cells while sparing normal cells.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Shin MK, Jang BY, Bu KB, Lee SH, Han DH, Oh JW, Sung JS. De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity. Int J Mol Sci. 2022 Dec 9;23(24):15594. doi: 10.3390/ijms232415594. PMID: 36555235; PMCID: PMC9779372.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.